Survival and Ventricular Enlargement Study (SAVE)

A randomized, placebo-controlled, multicenter clinical trial in 40 centers that tested the effectiveness of captopril in reducing total mortality and/or ventricular enlargement in 2,231 post-myocardial infarction patients.

Sponsored by Bristol-Myers-Squibb, Inc.; 1986–1993 ($1,959,014).

Final Paper

Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.

Design Paper

Moyé LA, Pfeffer MA, Braunwald E, for the SAVE Investigators. Rationale, design and baseline characteristics of the Survival and Ventricular Enlargement Trial (SAVE). Am J Cardiol 1991;68:70D-9D.

All Papers